Table 2.

Univariate and multivariable analyses of NLR associations with outcomes in IPI group.

			Univariate analysis		Multivariable analysis
			HR (95%CI)	p Value	HR (95%CI)	p Value
OS
Baseline	Baseline NLR ≥ 5 (ref: < 5)		2.08 (1.52, 2.83)	< 0.001	2.03 (1.49, 2.77)	< 0.001
	M stage C (ref = others)		2.17 (1.45, 3.25)	< 0.001	2.07 (1.38, 3.13)	< 0.001
	Melanoma type (ref = mucosal):	Ocular	0.49 (0.22, 1.06)	0.024	0.53 (0.24, 1.17)	0.085
		Cutaneous/not specified	0.45 (0.25, 0.8)		0.52 (0.29, 0.93)
Week 3	Week 3 NLR ≥ 5 (ref: < 5)		2.89 (2.05, 4.07)	< 0.001	2.82 (2.00, 4.00)	< 0.001
	M stage C (ref = others)		2.09 (1.38, 3.15)	< 0.001	1.97 (1.3, 3.01)	0.002
	Melanoma type (ref = mucosal):	Ocular	0.42 (0.19, 0.94)	0.006	0.48 (0.22, 1.08)	0.034
		Cutaneous/not specified	0.39 (0.22, 0.69)		0.46 (0.25, 0.82)
Week 6	Week 6 NLR ≥ 5 (ref: < 5)		3.50 (2.37, 5.17)	< 0.001	3.37 (2.26, 5.04)	< 0.001
	M stage C (ref = others)		1.97 (1.26, 3.08)	0.003	1.85 (1.17, 2.92)	0.008
	Melanoma type (ref = mucosal):	Ocular	0.30 (0.13,0.74)	< 0.001	0.42 (0.17, 1.04)	0.005
		Cutaneous/not specified	0.27 (0.15, 0.51)		0.36 (0.19, 0.66)
Week 9	Week 9 NLR ≥ 5 (ref: < 5)		2.26 (1.49,3.43)	< 0.001	2.06 (1.33, 3.19)	0.001
	M stage C (ref = others)		2.14 (1.30, 3.50)	0.003	2.01 (1.22, 3.33)	0.006
	Melanoma type (ref = mucosal):	Ocular	0.32 (0.12, 0.88)	0.008	0.28 (0.10, 0.78)	0.038
		Cutaneous/not specified	0.32 (0.16, 0.66)		0.45 (0.22, 0.94)
PFS
Baseline	Baseline NLR ≥ 5 (ref: < 5)		1.81 (1.34, 2.45)	< 0.001	1.81 (1.33, 2.45)	< 0.001
	M stage C (ref = others)		2.28 (1.54, 3.38)	< 0.001	2.19 (1.48, 3.25)	< 0.001
	Gender male (ref = female)		0.66 (0.49, 0.90)	0.008	0.67 (0.50, 0.91)	0.011
Week 3	Week 3 NLR ≥ 5 (ref: < 5)		2.37 (1.69, 3.32)	< 0.001	2.26 (1.62, 3.17)	< 0.001
	M stage C (ref = others)		2.19 (1.46, 3.27)	< 0.001	2.10 (1.41, 3.14)	< 0.001
	Gender male (ref = female)		0.64 (0.46, 0.88)	0.007	0.68 (0.49, 0.94)	0.018
Week 6	Week 6 NLR ≥ 5 (ref: < 5)		2.68 (1.82, 3.96)	< 0.001	2.51 (1.70, 3.72)	< 0.001
	M stage C (ref = others)		2.06 (1.34, 3.18)	0.001	1.98 (1.28, 3.06)	0.002
	Gender male (ref = female)		0.63 (0.44, 0.91)	0.013	0.73 (0.50, 1.05)	0.087
Week 9	Week 9 NLR ≥ 5 (ref: < 5)		1.95 (1.27, 2.98)	0.002	2.10 (1.40, 3.16)	< 0.001
	M stage C (ref = others)		2.10 (1.29, 3.42)	0.003	2.02 (1.24, 3.29)	0.005
	Gender male (ref = female)		0.63 (0.42, 0.95)	0.028	0.74 (0.49, 1.12)	0.015

Clinical variables not listed in the table were not significant in multivariable analysis of any time point.